Diabetic or Idiopathic Gastroparesis

Updated on 25 March 2021


Diabetic or Idiopathic Gastroparesis


0099 : A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis.

Condition Diabetic Gastroparesis
Clinical Study IdentifierTX141618
Last Modified on25 March 2021


Yes No Not Sure

Inclusion Criteria

Symptoms of gastroparesis (eg, nausea, early satiety, fullness, bloating, upper abdominal pain, retching or vomiting) for at least 3 months prior to Screening
Composite score ≥2.5 and <5 on nausea, bloating, feeling excessively full after meals, and not able to finish a normal-sized meal items (on the GCSI-2W) at Screening
Delayed gastric emptying, defined as a gastric emptying retention >10% at 4 hours, as measured by 99mTc gastric emptying scintigraphy (GES) at Screening (unless a comparable, qualifying 4-hour GES within 1 year of Screening is available)
Upper gastrointestinal obstruction ruled out by endoscopy or other imaging (eg, computed tomography) after the onset of gastroparesis symptoms
Willing to abstain from prohibited medications, including but not limited to, anticholinergics, acetylcholinesterase antagonists, or promotility medications (eg, metoclopramide, domperidone, prucalopride, erythromycin) for 72 hours prior to GES during Screening, if applicable, and 72 hours prior to start of the Baseline period and then throughout the duration of the study
GCSI-DD 7-day mean composite score ≥2.5 and <5 at Day 1

Exclusion Criteria

If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level >10%
Prior history of gastric surgery, including but not limited to gastrectomy, gastric bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication, which has manipulated the natural anatomy of the stomach
History of intrapyloric botulinum toxin injection within 6 months of Screening or currently has functioning implantable electric stimulator
History of alcohol or drug abuse or dependence within the last year prior to Screening
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note